FCE 28260

FCE 28260
Systematic (IUPAC) name

(4aR,4bS,6aS,7S,9aS,9bS,11aR)-4a,6a-Dimethyl-2-oxo-N-((2RS)-1,1,1-trifluoro-2-phenyl-2-propanyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide
Clinical data
Routes of administration	Oral
Identifiers
ATC code	None
ChemSpider	117369
Chemical data
Formula	C₂₈H₃₅F₃N₂O₂
Molecular mass	488.58 g/mol
SMILES FC(F)(F)C(c1ccccc1)(NC(=O)[C@@H]3[C@]2(CC[C@H]4[C@H]([C@@H]2CC3)CC[C@H]5NC(=O)\C=C/[C@]45C)C)C
InChI InChI=1S/C28H35F3N2O2/c1-25-15-13-20-18(9-12-22-26(20,2)16-14-23(34)32-22)19(25)10-11-21(25)24(35)33-27(3,28(29,30)31)17-7-5-4-6-8-17/h4-8,14,16,18-22H,9-13,15H2,1-3H3,(H,32,34)(H,33,35)/t18-,19-,20-,21+,22+,25-,26+,27?/m0/s1 Key:FAIZUAWLKOHMOP-ZOIXLQFFSA-N

FCE 28260 is a 5-alpha-reductase inhibitor drug with antiandrogenic activity, which was developed for the treatment of benign prostatic hyperplasia and androgenic (or androgenetic) alopecia in the 1990s.^[1]^[2] Its current status is unknown.

In a 1996 study, FCE 28260 inhibited rat and human 5-alpha-reductase with half maximal inhibitory concentrations (IC₅₀) of 15 and 16 nM, respectively, while finasteride had values of 30 and 52 nM.^[1]

References

↑ 1.0 1.1 Giudici, D.; Briatico, G.; Cominato, C.; Zaccheo, T.; Iehlè, C.; Nesi, M.; Panzeri, A.; Di Salle, E. (1996). "FCE 28260, a new 5 alpha-reductase inhibitor: In vitro and in vivo effects". The Journal of Steroid Biochemistry and Molecular Biology 58 (3): 299–305. doi:10.1016/0960-0760(96)00040-4. PMID 8836165.
↑ EP 0782582, Salle Enrico Di, Marcella Nesi, Achille Panzeri, "Epimers of (22RS)-N-(1,1,1-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide", published 1997-07-09 .